Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now

Key Takeaways BIO's Clinical Diagnostics returned to normalized growth, supported by strong platforms and automation up. BIO generates 59% of its revenues internationally, led by Europe, with gradual funding improvements expected.BIO faces currency headwinds, as inflation, China policy shifts and a strong dollar pressure revenues. Bio-Rad Laboratories, Inc. (BIO) is well-poised to grow in the upcoming quarters, given the demand for its quality control and immunology products in Clinical Diagnostics. In addi ...